PV Bulletin

IB template for cell therapy products

A new Investigator’s Brochure (IB) template for cell therapy products has been released by the Danish Medicines Agency.

Primary source: Danish Medicines Agency (Lægemiddelstyrelsen)

PV Impact Brief

Urgency: HighConfidence: high

What changed

Availability of a new Investigator’s Brochure (IB) template specifically for cell therapy products.

Why it matters

This standardization ensures consistent documentation of risk assessments and safety data, enhancing oversight during clinical trials.

Action needed

Utilize the IB template provided for cell therapy products in clinical trial applications, available under the 'Special Product Areas' section of the Danish Medicines Agency's website.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
Inspection Readiness
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Template
Policy status
new
Publication date
2026-06-25
Policy change
The Danish Medicines Agency released a new Investigator’s Brochure (IB) template specifically tailored for cell therapy products to streamline clinical trial applications and ensure comprehensive safety data reporting.

Key changes

Standardization of the IB format for cell therapy trials in Denmark.

Affected workflows

Inspection Readiness

Responsible groups

Clinical OperationsPV OperationsRegulatory Affairs

PV impact

Ensures that risk assessments and safety data for cell therapies are consistently documented in the IB, facilitating better safety oversight during clinical trials.

View regulator source

Source document details

Exact policy details

IB Template Availability
Available
Applies to: For cell therapy products
An IB template for cell therapy products is now available · p. 1 · High · Source
Guidance Location
Special Product Areas under Regulation of innovative medicinal products
Applies to: Clinical trial applications
The documents can be found under 'Special Product Areas', within 'Regulation of innovative medicinal products' · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 25, 2026

Full briefing

Practical implication

Utilize the IB template provided for cell therapy products in clinical trial applications, available under the 'Special Product Areas' section of the Danish Medicines Agency's website.

The Danish Medicines Agency introduced an IB template specifically for cell therapy products to standardize clinical trial applications and improve safety data reporting.

What changed: Availability of a new Investigator’s Brochure (IB) template specifically for cell therapy products.

Why it matters: This standardization ensures consistent documentation of risk assessments and safety data, enhancing oversight during clinical trials.

Practical implication: Utilize the IB template provided for cell therapy products in clinical trial applications, available under the 'Special Product Areas' section of the Danish Medicines Agency's website.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Template#new#Danish Medicines Agency (Lægemiddelstyrelsen)#reporting_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward